Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Oana Danciu, M.D.
Big Ten Cancer Research Consortium
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Illinois Cancer Center
Chicago, Illinois, United States
- Michigan State University
Lansing, Michigan, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Penn State Cancer Institute
Hershey, Pennsylvania, United States
- University of Wisconsin
Madison, Wisconsin, United States
- Prohealth Care
Waukesha, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Feb 2017
- Primary completion
- 3 Jul 2023
- Completion
- 24 Oct 2023
- Last update posted
- 20 Jan 2026
- Registered enrollment
- 49
- Registry id
- NCT02668666
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.